Developing innovative treatments for horses
Cellavos AB developed a technology in which MSCs derived from the bone marrow of donor horses are expanded in laboratory conditions to get enough cells to treat a number of horses.
What we do
Cellavos AB was founded in 2016 with the aim to develop innovative treatments for horses based on mesenchymal stromal cells (MSC). The company developed a technology in which MSCs derived from the bone marrow of donor horses are expanded in laboratory conditions to get enough cells to treat a number of horses.
More than 300 horses have been treated for various diseases (chronic gonitis, arthrosis, desmitis, tendinitis etc. ) in a preclinical study with 84 % success rate. The results from those treatments form a stable base for a clinical development program aiming at registered products. Cellavos has its own laboratory in Sweden with a standardized methodology strictly regulated by SOPs.
There are MSC-based products registered on the market for veterinary applications, but the opinion is that they present limits, therefore superior products are needed.
A clinical program is under development and a clinical network has been established.
For a second generation of products Cellavos envision a therapy based on MSCs derived extracellular vesicles (EVs) that are considered to be the messengers bringing several of the therapeutic effects of MSCs. Such products would be easier to transport, store and administer for the veterinarians.
Cellavos is a subsidiary (65 %) to Takura AB